Sangamo Therapeutics' GAAP loss for three months of 2021 was $45.939 million, up 6.9% from $42.974 million in the previous year. Revenue doubled to $26.28 million from $13.076 million a year earlier.
Sangamo Therapeutics' GAAP loss for three months of 2021 was $45.939 million, up 6.9% from $42.974 million in the previous year. Revenue doubled to $26.28 million from $13.076 million a year earlier. 
investor.sangamo.com
English (US) 